The rationale for not applying endocrine therapies in the adjuvant management of prostate cancer after prostatectomy is provided by multiple clinical trials, which illustrated limited to no clinical benefit of blocking AR function on disease-free survival of the entire population (Zincke et al, 2001; Dorff et al, 2011; Miocinovic et al, 2011; Siddiqui et al, 2011; Briganti et al, 2012; Schubert et al, 2012; Tsurumaki Sato et al, 2014). This evidence concerns the gene AR and Familial prostate cancer.